Cargando…

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been an important therapeutic advancement in the field of cancer medicine. Recent reports provided greater insights into the cardiovascular adverse events, which prohibited the use of ICIs. Cardiovascular adverse events occur in different forms, s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Wenzheng, Chen, Hanbin, Chen, Didi, Ye, Yijia, Xie, Congying, Hou, Meng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594538/ https://www.ncbi.nlm.nih.gov/pubmed/33115945 http://dx.doi.org/10.1136/jitc-2020-001293

Ejemplares similares

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2021)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
por: Yamaguchi, Yukiko, et al.
Publicado: (2022)

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
por: Chesney, Jason, et al.
Publicado: (2022)

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
por: Prokopi, Anastasia, et al.
Publicado: (2021)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
por: Marotte, Lucine, et al.
Publicado: (2020)

Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6
por: Lee, Young Eun, et al.
Publicado: (2023)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

Hypoxia-inducible lentiviral gene expression in engineered human macrophages
por: Chinn, Harrison K, et al.
Publicado: (2022)

Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
por: Arranz-Nicolás, Javier, et al.
Publicado: (2020)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages
por: Meziani, Lydia, et al.
Publicado: (2020)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
por: Poznanski, Sophie M, et al.
Publicado: (2021)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response
por: Wang, Yi-Na, et al.
Publicado: (2023)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma
por: Yu, Zhuo, et al.
Publicado: (2022)

Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
por: Liu, Dan, et al.
Publicado: (2021)

Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β
por: Brownlie, Demi, et al.
Publicado: (2021)

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor
por: Gao, Ge, et al.
Publicado: (2023)

HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
por: Chen, Alan Chen, et al.
Publicado: (2020)

Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
por: Liu, Lunan, et al.
Publicado: (2022)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
por: Bi, Jiacheng, et al.
Publicado: (2023)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
por: Lu, Yong-Chen, et al.
Publicado: (2021)

High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
por: Clara, Joseph Andrew, et al.
Publicado: (2022)

Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1(157-165) tumor-specific peptide
por: Shenderov, Eugene, et al.
Publicado: (2021)

Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy
por: He, Huan, et al.
Publicado: (2021)

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
por: Xiong, Chengjie, et al.
Publicado: (2022)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors
por: Hu, Jiemiao, et al.
Publicado: (2022)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
por: Leko, Vid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_36ogf55dekmd2hioaji4eeh601